• Explore /
  • Poster
  • / First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) variant: Randomized phase 2b trial.

First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) variant: Randomized phase 2b trial.

Abstract Poster

Authors

null

Rahul Raj Aggarwal

University of California, San Francisco, San Francisco, CA

Rahul Raj Aggarwal , Jingsong Zhang , Paul Monk III, Xinhua Zhu , Dan Costin , Daniel P. Petrylak , Pascal Borderies , Rashmi Majali Deshpande , Amir Hafeez , Vincent J. O'Neill , Scott T. Tagawa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT03910660

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS5109)

DOI

10.1200/JCO.2023.41.16_suppl.TPS5109

Abstract #

TPS5109

Poster Bd #

197b

Abstract Disclosures

Similar Posters

First Author: Scott T. Tagawa

First Author: Jingsong Zhang

First Author: Rahul Raj Aggarwal

First Author: Evan Y. Yu